
News|Articles|February 1, 2003
- Applied Clinical Trials-02-01-2003
New Ways to Recruit Trial Subjects
Author(s)Faiz Kermani, Ph.D, Pietro Bonacossa
To minimize time to market, sponsors must explore new subject recruitment techniques.
Advertisement
Clinical trials are a vital step toward bringing new drugs to market. U.S.-based clinical trial activities increased by 6% in 2001, the largest rise since 1990.1 But although pharmaceutical companies pay close attention to the science when designing their clinical trials, few consider how they will get enough subjects to participate. As a result, most trials are plagued by delays that can cost pharmaceutical companies millions of missed sales. Delays in getting a drug to market are estimated to cost companies around $1 million a day.2
Articles in this issue
almost 24 years ago
Clinical Trials in Indiaalmost 24 years ago
Using Mock Inspections to Prepare for FDA GCP Inspectionsalmost 24 years ago
Tweaking the EU Rules on Clinical Trialsalmost 24 years ago
AIDS Campaign Spotlights Global Clinical Researchalmost 24 years ago
The Woodsman?s Talealmost 24 years ago
A 6-Month Process for Planning Multinational Clinical TrialsAdvertisement
Related to this article

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, makes the case that oncologists must lead discussions about randomization and treatment decisions, while AI can prepare patients beforehand and support them afterward.

Participants in a survey of 354 pre-screening respondents rated AI voice-assisted screening (Clara) favorably and were more likely to schedule and attend study appointments than web-form users, though self-selection means the association cannot be read as causal.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains how AI can unlock unstructured chart data and cut coordinator screening time from hours to minutes, easing a clinical research workforce under strain.

In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, describes how physician awareness and site-level access drive screening inconsistencies, and why acceptance rates are the same across backgrounds once patients are simply asked.

The agency is still accepting applications but is not reviewing or granting new ones, according to Reuters, while HHS says work under the program is ongoing.

In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How AI-Enabled Trial Matching Is Changing Who Gets Identified and Screened
2
Participant Experience with AI-Assisted and Web-Based Clinical Trial Pre-Screening
3
Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial
4
Where AI Helps in Patient Conversations About Trials and Where Humans Must Lead
5

